NCT00970502View on ClinicalTrials.gov

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Cancer of the PharynxCancer of the LarynxCancer of the NeckParanasal Sinus NeoplasmsCancer of the Head
Interventions
DRUG

erlotinib + celecoxib

In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression

Trial Locations (1)

10029

Mount Sinai School of Medicine, New York

All Listed Sponsors
lead

Johnny Kao

OTHER

NCT00970502 - Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer | Biotech Hunter | Biotech Hunter